Skip to main content
OpenTrials
Completed

NCT Number: NCT07272733

Early Detection, Remote Augmented Reality Combined Rehabilitation Therapy, and Translational Therapy for Patients With Chronic Kidney Disease and Cognitive Disorder

More than half of the patients with nephropathy have cognitive impairment, which can reach the level of dementia.The decline of renal function is more serious. With the aging of the population and changes in lifestyle, the number of patients is increasing day by day. The reasons are 1.Chronic kidney disease is prone to sarcopenia due to restricted protein intake, and even affects the heart and brain other than the kidneys. 2. Often accompanied by limb weakness and inconvenience of movement, sometimes it is very inconvenient to go to the hospital for treatment, so the hospital is the center cardio to perform telerehabilitation therapy is another option, so the purpose of this study is for patients with cognitive impairment Rehabilitation in virtual reality at a distance to evaluate its effectiveness. In this study, we selected from the treatment room of Beijing Medical Rehabilitation Department choose a space, simulate the situation of home telerehabilitation, and implement virtual reality telerehabilitation with the hospital as the center. The effect of distance rehabilitation and traditional rehabilitation. The study is expected to recruit 60 patients with chronic cognitive impairment and kidney disease who will be randomized. Divided into two groups A, B and C for training, 20 patients in each group, of which group A received ketoacid amino acid supplementation therapy, 3 capsules per day for 3 months; patients in group B received telerehabilitation for 30 minutes three days a week for a total of 3 months; C C The group was the control group, and the treatment was carried out according to the medical routine. The 60 patients received cognitive function,Brain functional MRI, balance ability, clinical function, clinical physical data, daily living function and depression Index evaluation. The results of this study can be used as a reference for future home tele-rehabilitation and ketoacid amino acid supplementation.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Chronic kidney disease stage 3-5

Exclusion criteria

  • without cognitive disorder

Treatment and study plan

Ketosteril

Drug

Ketosteril will lower protein binded uremic toxin

Primary outcomes

  1. MMSE

    Time frame: Half a year

    Cognitive test

Sponsors and collaborators

Lead sponsor

Taipei Medical University Hospital

Other

Registry information

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Dec 9, 2025
Registry last updated
Dec 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.